I-Mab appointed Raj Kannan as the new CEO and a member of the board of directors effective June 22. Raj Kannan has over 30 years of industry experience as a biotech CEO, more recently as CEO of Aerie Pharmaceuticals, and before that of Chiasma Pharmaceuticals.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on IMAB: